Panagora Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,282
| Closed | -$239K | – | 1323 |
|
|
2023
Q2 | $239K | Buy |
+12,282
| New | +$291K | ﹤0.01% | 1149 |
|
|
2022
Q4 | – | Sell |
-11,012
| Closed | -$291K | – | 1521 |
|
|
2022
Q3 | $291K | Buy |
11,012
+3,922
| +55% | +$144K | ﹤0.01% | 1284 |
|
|
2022
Q2 | $315K | Hold |
7,090
| – | – | ﹤0.01% | 1297 |
|
|
2022
Q1 | $351K | Hold |
7,090
| – | – | ﹤0.01% | 1322 |
|
|
2021
Q4 | $361K | Hold |
7,090
| – | – | ﹤0.01% | 1327 |
|
|
2021
Q3 | $395K | Sell |
7,090
-8,932
| -56% | -$439K | ﹤0.01% | 1404 |
|
|
2021
Q2 | $686K | Buy |
16,022
+15,733
| +5,444% | +$649K | ﹤0.01% | 1190 |
|
|
2021
Q1 | $12K | Sell |
289
-13,736
| -98% | -$638K | ﹤0.01% | 2370 |
|
|
2020
Q4 | $653K | Hold |
14,025
| – | – | ﹤0.01% | 1132 |
|
|
2020
Q3 | $596K | Sell |
14,025
-492
| -3% | -$21.5K | ﹤0.01% | 1096 |
|
|
2020
Q2 | $697K | Sell |
14,517
-26,873
| -65% | -$1.34M | ﹤0.01% | 1071 |
|
|
2020
Q1 | $1.9M | Sell |
41,390
-67,024
| -62% | -$3.36M | 0.01% | 606 |
|
|
2019
Q4 | $6.51M | Buy |
108,414
+13,168
| +14% | +$785K | 0.03% | 421 |
|
|
2019
Q3 | $5.39M | Sell |
95,246
-3,197
| -3% | -$180K | 0.02% | 442 |
|
|
2019
Q2 | $5.48M | Sell |
98,443
-18,602
| -16% | -$970K | 0.02% | 472 |
|
|
2019
Q1 | $5.91M | Buy |
117,045
+50,314
| +75% | +$2.24M | 0.03% | 465 |
|
|
2018
Q4 | $2.69M | Buy |
66,731
+7,611
| +13% | +$392K | 0.01% | 665 |
|
|
2018
Q3 | $4.1M | Buy |
59,120
+17,441
| +42% | +$1.32M | 0.02% | 581 |
|
|
2018
Q2 | $3.15M | Buy |
+41,679
| New | +$2.62M | 0.01% | 707 |
|
|
2017
Q3 | – | Sell |
-70,806
| Closed | -$5.59M | – | 2525 |
|
|
2017
Q2 | $5.59M | Buy |
70,806
+14,240
| +25% | +$1.16M | 0.02% | 543 |
|
|
2017
Q1 | $4.69M | Sell |
56,566
-1,195
| -2% | -$88.8K | 0.02% | 603 |
|
|
2016
Q4 | $4.58M | Buy |
57,761
+704
| +1% | +$51.1K | 0.02% | 592 |
|
|
2016
Q3 | $3.99M | Sell |
57,057
-22,483
| -28% | -$1.25M | 0.02% | 627 |
|
|
2016
Q2 | $3.08M | Buy |
79,540
+3,038
| +4% | +$127K | 0.02% | 713 |
|
|
2016
Q1 | $3.1M | Buy |
76,502
+41,901
| +121% | +$2.66M | 0.02% | 725 |
|
|
2015
Q4 | $3.07M | Buy |
34,601
+7,760
| +29% | +$613K | 0.02% | 683 |
|
|
2015
Q3 | $1.99M | Buy |
26,841
+4,578
| +21% | +$381K | 0.01% | 771 |
|
|
2015
Q2 | $1.8M | Buy |
22,263
+10,164
| +84% | +$662K | 0.01% | 839 |
|
|
2015
Q1 | $507K | Buy |
+12,099
| New | +$343K | ﹤0.01% | 1310 |
|
Other funds holding EGRX
BIP
Panagora Asset Management's EGRX Position: Q3 2023 in Review
Panagora Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 12,282 shares — an estimated $239K sold.
Panagora Asset Management first reported a position in EGRX in Q1 2015 and held it in 29 quarters. The position peaked at $6.51M in Q4 2019. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.
- Panagora Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Panagora Asset Management sold 12,282 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $239K.
- Panagora Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 29 quarters.
- Panagora Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $6.51M in Q4 2019.
- 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.
Based on Panagora Asset Management's 13F filing for Q3 2023, filed 31 Oct 2023.